Journal
JOURNAL OF IMMUNOLOGY
Volume 199, Issue 7, Pages 2333-2342Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1601554
Keywords
-
Categories
Funding
- National Institutes of Health [AI129582, CA095426, CA185301, CA097189]
- American Cancer Society [RSG-14-243-01-LIB]
- Gabrielle's Angel Foundation for Cancer Research
- Leukemia and Lymphoma Society
Ask authors/readers for more resources
Group 3 innate lymphoid cells (ILC3s) are important regulators of the immune system, maintaining homeostasis in the presence of commensal bacteria, but activating immune defenses in response to microbial pathogens. ILC3s are a robust source of IL-22, a cytokine critical for stimulating the antimicrobial response. We sought to identify cytokines that can promote proliferation and induce or maintain IL-22 production by ILC3s and determine a molecular mechanism for this process. We identified IL-18 as a cytokine that cooperates with an ILC3 survival factor, IL-15, to induce proliferation of human ILC3s, as well as induce and maintain IL-22 production. To determine a mechanism of action, we examined the NF-kappa B pathway, which is activated by IL-18 signaling. We found that the NF-kB complex signaling component, p65, binds to the proximal region of the IL22 promoter and promotes transcriptional activity. Finally, we observed that CD11c(+) dendritic cells expressing IL-18 are found in close proximity to ILC3s in human tonsils in situ. Therefore, we identify a new mechanism by which human ILC3s proliferate and produce IL-22, and identify NF-kappa B as a potential therapeutic target to be considered in pathologic states characterized by overproduction of IL-18 and/or IL-22.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available